moderate persistent allergic asthma.
Conditions
Interventions
Intervention 1: Saffron consumer group which receiving 100 mg of saffron per day in capsule form (two 50 mg capsule per day). Drug producing center: growth center of Ahvaz Jundishapur University of m
Treatment - Drugs
Placebo
Saffron consumer group which receiving 100 mg of saffron per day in capsule form (two 50 mg capsule per day). Drug producing center: growth center of Ahvaz Jundishapur University of medical sciences.
Placebo consumer group: consumption two capsules per day which containing starch. Drug producing center: growth center of Ahvaz Jundishapur University of medical sciences. Duration of drug consumptio
Sponsors
Vice Chancellor for research of Ahvaz Jundishapur University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: age between 18 to 65 years old, moderate persistent allergic asthma (FEV1 between 40 to 60 percent) according to the physician and normal BMI (up to 27). Inclusion criteria dos not belong to the particular gender and include male and females. Exclusion criteria include smoking, diabetes, pregnancy and lactation, autoimmune disease, malignancies, gastrointestinal, liver and kidney disease, pneumonia and other pulmonary disease and Not wanting to continue cooperation
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Antibody titers to heat shock protein 70. Timepoint: Before and two months after intervention. Method of measurement: according to the Laboratory Measurement-ng/ml.;FEV1, FVC, FEV1/FVC. Timepoint: Before and two months after intervention. Method of measurement: According to the results of the spirometer-scale:percent. | — |
Secondary
| Measure | Time frame |
|---|---|
| HsCRP. Timepoint: Before and two months after intervention. Method of measurement: according to the laboratory measurement-mg/dl.;Lipid profile. Timepoint: Before and two months after intervention. Method of measurement: according to the laboratory measurement-mg/dl.;Blood presure. Timepoint: Before and two months after intervention. Method of measurement: according to the results of Sphygmomanometer-mmhg.;Clinical variables and the patient's general status. Timepoint: Before and two months after intervention. Method of measurement: according to the Questionnaires completed by physician superspecialty. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMarzie Zilaee
Department of nutrition, paramedicine school
Outcome results
None listed